ShawCopies of these posters will be available on the Trius Web site following theECCMID meeting: http:// Trius TherapeuticsTrius Therapeutics is discovering

ShawCopies of these posters will be available on the Trius Web site following theECCMID meeting: http:// Trius TherapeuticsTrius Therapeutics is discovering and developing innovative antibacterialdrugs for the treatment of infections caused by drug-resistant pathogens. Thecompany's lead drug candidate, torezolid, is a second generation oral and IVoxazolidinone antibiotic with potent activity against drug-resistantGram-positive bacterial pathogens including those resistant to Zyvox(R), theonly marketed antibacterial drug of the oxazolidinone class.Trius hasrecently completed Phase 2 testing of torezolid in a U.S based multi-centertrial. Trius' pipeline includes two preclinical programs with lead candidatesbeing developed to treat serious infections caused by Gram-negative bacterialpathogens. For more information, visit Therapeutics, Inc.Jason Spark of Porter Novelli Life Sciences, +1-619-849-6005,, for Trius Therapeutics, Inc.. Elyse S. Bluth of Duff & Phelps Elected to The ESOP Association's Board ofDirectorsWASHINGTON, May 6 /PRNewswire-USNewswire/ -- Elyse S.

Bluth, Managing Directorin Duff & Phelps's Chicago office, has been elected to the Board of Directorsof The ESOP Association.Ms. Bluth has been elected to serve a two-year,at-large slot representing a professional member on the Board of Directors. The ESOP Association is the national trade association for companies withemployee stock ownership plans (ESOPs) and the leading voice in America foremployee ownership.At Duff & Phelps, Ms. Bluth heads the firm's ESOP and ERISA Advisory Servicespractice focused on transactions and valuation services to employee benefitplans.She has more than 20 years of corporate finance experience includingmergers, acquisitions, divestitures, and valuation.The Board of Directors is the premier governing group in the Association. Seven members of the nine person Board of Directors are elected by theAssociation's Board of Governors.The core cause of The ESOP Association is the belief that employee ownershipwill improve American competitiveness, increase productivity through greateremployee participation, and strengthen our free enterprise economy.SOURCEThe ESOP AssociationAmy Gwiazdowski of The ESOP Association, +1-202-293-2971,. COLUMBIA, SC, May 06 (MARKET WIRE) -- BDI Pharma, Inc. (BDI) announced today that it is the first specialtybiopharmaceutical distributor to be recognized as an official authorizeddistributor for ATryn(R) (Antithrombin [Recombinant]).

"We recognize thechannel for this unique product's distribution is to be limited and arevery pleased to be the initial distributor of ATryn in the U.S.," saidWilliam Shirey, Executive Vice President of BDI. "We, at BDI, embrace thepartnership with Lundbeck and welcome the opportunity to introduce arecombinant antithrombin to our nation's healthcare community."ATryn is approved by the U.S. Food and Drug Administration (FDA) for theprevention of perioperative and peripartum thromboembolic events inpatients with hereditary antithrombin deficiency.About ATryn--In 2006, ATryn was approved in the European Union through thecentralized procedure.--ATryn was developed to provide a safe, efficacious and consistentrecombinant antithrombin that is readily available. Recombinantantithrombin has the same amino acid sequence as antithrombin derived fromhuman plasma. The glycosylation profile of recombinant antithrombin isdifferent from plasma derived antithrombin, which results in an increasedheparin affinity. When assayed in the presence of excess of heparin thepotency of the recombinant product is not different from that of plasmaderived product.--ATryn does not carry the risk of transmission of human blood bornediseases. Additionally, antithrombin concentrate from human plasmaexperienced supply shortages in the past while ATryn's unique manufacturingprocess enables a safe and consistent supply of recombinant humanantithrombin.About BDI Pharma, Inc.Serving the healthcare community since 1995, BDI Pharma, Inc., thepreeminent national wholesaler of specialty biopharmaceutical products,has built an outstanding reputation as an industry source for products andservice.

BDI Pharma's market focus is evident in its commitment tospecialty biotherapeutics, chemotherapies, immunologics and hemostatics,including Albumin (Human) USP, intravenous immune globulin (IVIG or IGIV),coagulation factors VIII, IX, and VIIa, as well as hyper-immunes,injectables and physician specialty pharmaceuticals. As a recognizedAuthorized Distributor of Record for the products it supplies nationwide,BDI Pharma services the entire country and is fully accredited andinsured, fulfilling the licensing requirements in all 50 states.In an arena where access to pertinent clinical data and updatedinformation on market availability is paramount to patient care, BDIPharma defines its customer-centric approach to serving the nation'shealthcare community through innovative inventory management programs,unparalleled customer service, extensive product knowledge, uniquepromotional services, emergency availability and urgent need delivery.The company serves as a source for reference material and market data,offering healthcare providers the latest information on products, supplyand other industry events. BDI Pharma's educational literature and Website -- -- serve as open-access resources, contributingto the promotion of the biopharmaceutical industry and the education ofboth the healthcare community and general populace.Contact:Brad DavisDirector of MarketingEmail Contact(800)948-9834Copyright 2009, Market Wire, All rights reserved.-0-. Yongye Biotechnology International Announces Conference Call to Discuss FirstQuarter Fiscal Year 2009 ResultsBEIJING, May 6 /PRNewswire-Asia-FirstCall/ -- Yongye BiotechnologyInternational, Inc.